Ser3252
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser3252 - EPPK1 (human)

Site Information
LRRQVSAsELHTSGI    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: EPPK1 (mouse): S3222, EPPK1 (rat): S3126
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
Disease tissue studied: cervical cancer (8), cervical adenocarcinoma (8), lung cancer (3, 4), non-small cell lung cancer (3, 4), non-small cell lung adenocarcinoma (4), non-small cell squamous cell lung carcinoma (3)
Relevant cell line - cell type - tissue: 293 (epithelial) (1, 2), 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] (7), DV-90 (pulmonary) (4), HeLa (cervical) (6, 19, 20, 21), HeLa S3 (cervical) (8), HepG2 (hepatic) (9, 11, 12, 16, 18), NCI-H2170 (squamous) (3), NCI-H2228 (pulmonary) (10, 13, 14), NCI-H3255 (pulmonary) (15, 17)

Controlled by
Treatments: angiotensin 2 (7), NaCl (1), SII angiotensin 2 (7)



References

1

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

2

(2011) CST Curation Set: 12825; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

3

(2011) CST Curation Set: 10916; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

4

(2011) CST Curation Set: 10896; Year: 2011; Biosample/Treatment: cell line, DV-90/untreated; Disease: lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

5

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

6

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

7

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

8

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

9

(2009) CST Curation Set: 7408; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

10

(2009) CST Curation Set: 7409; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

11

(2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

12

(2009) CST Curation Set: 7395; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

13

(2009) CST Curation Set: 7391; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/-; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

14

(2009) CST Curation Set: 7392; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/-; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

15

(2009) CST Curation Set: 7393; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

16

(2009) CST Curation Set: 7390; Year: 2009; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

17

(2009) CST Curation Set: 7323; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

18

(2009) CST Curation Set: 7319; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

19

(2009) CST Curation Set: 6245; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

20

(2009) CST Curation Set: 6244; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

21

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.